Literature DB >> 19276183

Extracellular matrix-induced gene expression in human breast cancer cells.

Nandor Garamszegi1, Susanna P Garamszegi, Lina A Shehadeh, Sean P Scully.   

Abstract

Extracellular matrix (ECM) molecules modify gene expression through attachment-dependent (focal adhesion-related) integrin receptor signaling. It was previously unknown whether the same molecules acting as soluble peptides could generate signal cascades without the associated mechanical anchoring, a condition that may be encountered during matrix remodeling and degradation and relevant to invasion and metastatic processes. In the current study, the role of ECM ligand-regulated gene expression through this attachment-independent process was examined. It was observed that fibronectin, laminin, and collagen type I and II induce Smad2 activation in MCF-10A and MCF-7 cells. This activation is not caused by transforming growth factor (TGF)-beta ligand contamination or autocrine TGF involvement and is 3- to 5-fold less robust than the TGF-beta1 ligand. The resulting nuclear translocation of Smad4 in response to ECM ligand indicates downstream transcriptional responses occurring. Coimmunoprecipitation experiments determined that collagen type II and laminin act through interaction with integrin alpha(2)beta(1) receptor complex. The ECM ligand-induced Smad activation (termed signaling crosstalk) resulted in cell type and ligand-specific transcriptional changes, which are distinct from the TGF-beta ligand-induced responses. These findings show that cell-matrix communication is more complex than previously thought. Soluble ECM peptides drive transcriptional regulation through corresponding adhesion and non-attachment-related processes. The resultant gene expressional patterns correlate with pathway activity and not by the extent of Smad activation. These results extend the complexity and the existing paradigms of ECM-cell communication to ECM ligand regulation without the necessity of mechanical coupling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276183      PMCID: PMC2681181          DOI: 10.1158/1541-7786.MCR-08-0227

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

Review 1.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 2.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Authors:  Jayanta Debnath; Senthil K Muthuswamy; Joan S Brugge
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

Review 4.  Modelling glandular epithelial cancers in three-dimensional cultures.

Authors:  Jayanta Debnath; Joan S Brugge
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

5.  Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin.

Authors:  Marguerite S Buzza; Laura Zamurs; Jiuru Sun; Catherina H Bird; A Ian Smith; Joseph A Trapani; Christopher J Froelich; Edouard C Nice; Phillip I Bird
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

6.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover.

Authors:  Gianni M Di Guglielmo; Christine Le Roy; Anne F Goodfellow; Jeffrey L Wrana
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

7.  Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody.

Authors:  I G Otterness; J T Downs; C Lane; M L Bliven; H Stukenbrok; D N Scampoli; A J Milici; P S Mézes
Journal:  Matrix Biol       Date:  1999-08       Impact factor: 11.583

8.  Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1.

Authors:  J S Munger; J G Harpel; F G Giancotti; D B Rifkin
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  Motile chondrocytes from newborn calf: migration properties and synthesis of collagen II.

Authors:  C Chang; D A Lauffenburger; T I Morales
Journal:  Osteoarthritis Cartilage       Date:  2003-08       Impact factor: 6.576

10.  Signal processing in the TGF-beta superfamily ligand-receptor network.

Authors:  Jose M G Vilar; Ronald Jansen; Chris Sander
Journal:  PLoS Comput Biol       Date:  2006-01-27       Impact factor: 4.475

View more
  13 in total

1.  Ligand-independent transforming growth factor-β type I receptor signalling mediates type I collagen-induced epithelial-mesenchymal transition.

Authors:  Lucas DeMaio; Stephen T Buckley; Manda S Krishnaveni; Per Flodby; Mickael Dubourd; Agnes Banfalvi; Yiming Xing; Carsten Ehrhardt; Parviz Minoo; Beiyun Zhou; Edward D Crandall; Zea Borok
Journal:  J Pathol       Date:  2011-12-09       Impact factor: 7.996

2.  The impact of adhesion peptides within hydrogels on the phenotype and signaling of normal and cancerous mammary epithelial cells.

Authors:  Michael S Weiss; Beatriz Peñalver Bernabé; Ariella Shikanov; Dennis A Bluver; Michael D Mui; Seungjin Shin; Linda J Broadbelt; Lonnie D Shea
Journal:  Biomaterials       Date:  2012-02-15       Impact factor: 12.479

3.  α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).

Authors:  Dalila Naci; Mohammed-Amine El Azreq; Nizar Chetoui; Laura Lauden; François Sigaux; Dominique Charron; Reem Al-Daccak; Fawzi Aoudjit
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

4.  Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.

Authors:  Michael W Pickup; Hanane Laklai; Irene Acerbi; Philip Owens; Agnieszka E Gorska; Anna Chytil; Mary Aakre; Valerie M Weaver; Harold L Moses
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

5.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

6.  Controlled spatial and conformational display of immobilised bone morphogenetic protein-2 and osteopontin signalling motifs regulates osteoblast adhesion and differentiation in vitro.

Authors:  Elizabeth A Mitchell; Benjamin T Chaffey; Andrew W McCaskie; Jeremy H Lakey; Mark A Birch
Journal:  BMC Biol       Date:  2010-05-10       Impact factor: 7.431

Review 7.  Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.

Authors:  Colleen S Curran; Patricia J Keely
Journal:  Matrix Biol       Date:  2012-12-20       Impact factor: 11.583

8.  The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype.

Authors:  Patricia Santos-Valle; Irene Guijarro-Muñoz; Angel M Cuesta; Vanesa Alonso-Camino; Maider Villate; Ana Alvarez-Cienfuegos; Francisco J Blanco; Laura Sanz; Luis Alvarez-Vallina
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

Review 9.  Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment.

Authors:  María Belén Giorello; Francisco Raúl Borzone; Vivian Labovsky; Flavia Valeria Piccioni; Norma Alejandra Chasseing
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-04       Impact factor: 2.673

10.  Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines.

Authors:  Caroline Gest; Ulrich Joimel; Limin Huang; Linda-Louise Pritchard; Alexandre Petit; Charlène Dulong; Catherine Buquet; Chao-Quan Hu; Pezhman Mirshahi; Marc Laurent; Françoise Fauvel-Lafève; Lionel Cazin; Jean-Pierre Vannier; He Lu; Jeannette Soria; Hong Li; Rémi Varin; Claudine Soria
Journal:  BMC Cancer       Date:  2013-02-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.